3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Plasmacytoma
2
Paraproteinemias
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Plasma Cell
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Prostatic Neoplasms
1
Patient Preference
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leiomyoma
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
CD20-positive Hematological Malignancies
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Breast Neoplasms
×
Injections, Subcutaneous
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts